EMA lists neurological disorder as 'very rare' side effect of AstraZeneca Covid jab

To date, some 833 cases of the disorder have been reported out of 592 million doses of the Oxford University/AstraZeneca 'Vaxzevria' Covid-19 vaccine administered worldwide up to July 31. File Picture: PA

The European Medicines Agency (EMA) has listed the neurological disorder Guillain-Barre syndrome (GBS) on its list of "very rare" side effects of the AstraZeneca (AZ) Covid-19 vaccine.

In a new safety report update on the AZ vaccine issued Wednesday, the EMA said that a causal relationship between the AZ ‘Vaxzevria’ jab and GBS was “at least a reasonable possibility.”